Jazz Pharmaceuticals
JAZZ
481 hedge funds and large institutions have $6.97B invested in Jazz Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 182 increasing their positions, 162 reducing their positions, and 68 closing their positions.
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 162
2.08% more ownership
Funds ownership: 90.78% → 92.86% (+2.1%)
1% less capital invested
Capital invested by funds: $7.03B → $6.97B (-$57.6M)
4% less funds holding
Funds holding: 500 → 481 (-19)
18% less call options, than puts
Call options by funds: $19.5M | Put options by funds: $23.9M
21% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$175M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$133M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$58.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$53.9M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$45.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$128M |
| 2 |
Swedbank
Stockholm,
Sweden
|
-$127M |
| 3 |
AC
Armistice Capital
New York
|
-$80.1M |
| 4 |
Millennium Management
New York
|
-$69.2M |
| 5 |
SC
Samlyn Capital
New York
|
-$52M |
JAZZ Hedge Fund Activity: Q1 2024 in Review
481 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2024, worth a combined $6.97B — down 0.82% from $7.03B a quarter earlier.
Sellers outnumbered buyers: 68 funds closed out of JAZZ and 54 opened new positions — a net loss of 14 holders — while 162 trimmed existing stakes and 182 added.
The largest buyer was Capital World Investors, opening a new position worth an estimated $175M. The largest seller was Wellington Management Group, cutting an estimated $128M.
- 481 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2024, down from 500 in Q4 2023.
- Funds reported $6.97B of Jazz Pharmaceuticals stock for Q1 2024, down 0.82% quarter-over-quarter.
- 54 funds opened new Jazz Pharmaceuticals positions in Q1 2024 and 68 closed out, a net change of -14 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2024 was Capital World Investors, an estimated $175M added.
- The largest Jazz Pharmaceuticals seller in Q1 2024 was Wellington Management Group, an estimated $128M sold.
Based on aggregated 13F filings for Q1 2024.